文献速递浆细胞疾病

帕比司他联合硼替佐米和地塞米松:PANORAMA 1 试验中剂量强度与给药频率对安全性影响的分析

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
PubMed 文献 · Br J Haematol · 2017-06-27

PANORAMA 1 三期试验显示帕比司他联合硼替佐米和地塞米松较安慰剂联合方案显著延长无进展生存期,但不良事件和因不良事件停药率更高。本亚组分析比较方案规定的两个治疗阶段,发现第二阶段按计划降低硼替佐米给药频率后,两臂关键不良事件发生率均降低。帕比司他臂剂量强度分析显示因不良事件调整剂量导致第1-4周期两药剂量降低,暴露校正分析显示剂量调整后第一阶段血小板减少频率降低。

要点

  • 第二阶段降低硼替佐米给药频率后,帕比司他臂3/4级血小板减少从56.7%降至6.0%,腹泻从24.1%降至7.1%,乏力从16.3%降至1.8%。
  • 帕比司他臂按周期分析显示第1-4周期因不良事件调整剂量导致帕比司他和硼替佐米剂量降低。
  • 暴露校正分析显示剂量调整后第一阶段血小板减少频率降低。

核心结论

  • 帕比司他联合硼替佐米和地塞米松较安慰剂联合方案显著延长无进展生存期且具有临床意义,但帕比司他臂不良事件和因不良事件停药率更高。
  • 按计划降低硼替佐米给药频率后两臂关键不良事件发生率降低,提示优化给药方案可改善耐受性并可能改善患者结局。

研究设计与样本

  • PANORAMA 1(Panobinostat Oral in Multiple Myeloma 1)三期试验的亚组分析,比较方案规定的两个治疗阶段(TP1和TP2),两阶段中硼替佐米和地塞米松的给药频率不同。

主要发现

  • 帕比司他臂3/4级血小板减少发生率:TP1为56.7%,TP2为6.0%。
  • 帕比司他臂3/4级腹泻发生率:TP1为24.1%,TP2为7.1%。
  • 帕比司他臂3/4级乏力发生率:TP1为16.3%,TP2为1.8%。
  • 帕比司他臂按周期剂量强度分析显示第1-4周期因不良事件调整剂量导致帕比司他和硼替佐米剂量降低。
  • 暴露校正分析显示剂量调整后TP1血小板减少频率降低。

临床怎么用

  • 作者认为优化该方案的给药可能改善耐受性,并可能改善患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Panobinostat in combination with bortezomib and dexamethasone demonstrated a significant and clinically meaningful progression-free survival benefit compared with placebo, bortezomib and dexamethasone in the phase 3 PANORAMA 1 (Panobinostat Oral in Multiple Myeloma 1) trial. Despite this benefit, patients in the panobinostat arm experienced higher rates of adverse events (AEs) and higher rates of discontinuation due to AEs. This PANORAMA 1 subanalysis examined AEs between 2 treatment phases of the study (TP1 and TP2), in which administration frequency of bortezomib and dexamethasone differed per protocol. The incidences of several key AEs were lower in both arms following the planned reduction of bortezomib dosing frequency in TP2. In the panobinostat arm, rates of thrombocytopenia (grade 3/4: TP1, 56·7%; TP2, 6·0%), diarrhoea (grade 3/4: TP1, 24·1%; TP2, 7·1%), and fatigue (grade 3/4: TP1, 16·3%; TP2, 1·8%) were lower in TP2 compared with TP1. Dose intensity analysis of panobinostat and bortezomib by cycle in the panobinostat arm showed reductions of both agent doses during cycles 1-4 due to dose adjustments for AEs. Exposure-adjusted analysis demonstrated a reduction in thrombocytopenia frequency in TP1 following dose adjustment. These results suggest that optimization of dosing with this regimen could improve tolerability, potentially leading to improved patient outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. San-Miguel JF, Hungria VTM, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. Br J Haematol. 2017. PMID: 28653400. doi:10.1111/bjh.14821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。